Information Provided By:
Fly News Breaks for November 12, 2019
RETA
Nov 12, 2019 | 08:55 EDT
Baird analyst Brian Skorney raised his price target on Reata Pharmaceuticals to $245 from $162 following the positive Phase 3 readout of its CARDINAL study. The report showed a clear on-treatment washout effect of barboxolone that was clinically meaningful and statistically superior to the placebo on eGFR in patients with Alport Syndrome. Skorney reiterated his Outperform rating on Reata Pharmaceuticals shares.
News For RETA From the Last 2 Days
There are no results for your query RETA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.